Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications
Journal of Medicinal Chemistry · 11.04.2024 · 67 (7) · 5185-5215
DOI: 10.1021/acs.jmedchem.4c00312 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.04.2024. Verfasst von Yuming Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Neuro-system and Multimorbidity Laboratory and State Key Laboratory of Biotherapy and Cancer Center and National Clinical Re…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinases, Cyclin-Dependent Kinase 9. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 154 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Sichuan Province.
Abstract (Originalsprache)
CDK9 is a cyclin-dependent kinase that plays pivotal roles in multiple cellular functions including gene transcription, cell cycle regulation, DNA damage repair, and cellular differentiation. Targeting CDK9 is considered an attractive strategy for antitumor therapy, especially for leukemia and lymphoma. Several potent small molecule inhibitors, exemplified by TG02 (4), have progressed to clinical trials. However, many of them face challenges such as low clinical efficacy and multiple adverse reactions and may necessitate the exploration of novel strategies to lead to success in the clinic. In this perspective, we present a comprehensive overview of the structural characteristics, biological functions, and preclinical status of CDK9 inhibitors. Our focus extends to various types of inhibitors, including pan-inhibitors, selective inhibitors, dual-target inhibitors, degraders, PPI inhibitors, and natural products. The discussion encompasses chemical structures, structure-activity relationships (SARs), biological activities, selectivity, and therapeutic potential, providing detailed insight into the diverse landscape of CDK9 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Neuro-system and Multimorbidity Laboratory and State Key Laboratory of Biotherapy and Cancer Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University,…
- West China College of Medicine, West China Hospital, Sichuan University, Chengdu, 610041 Sichuan, China.
- School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, 610031 Sichuan, China.
ORCID-Profile: Jifa Zhang
Förderung
- National Natural Science Foundation of China
- Sichuan Province
Zitieren
APA
Zhang, Y., Shan, L., Tang, W., Ge, Y., Li, C., & Zhang, J. (2024). Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications. Journal of Medicinal Chemistry, 67(7), 5185-5215. https://doi.org/10.1021/acs.jmedchem.4c00312
Vancouver
Zhang Y, Shan L, Tang W, Ge Y, Li C, Zhang J. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications. Journal of Medicinal Chemistry. 2024;67(7):5185-5215. doi:10.1021/acs.jmedchem.4c00312
BibTeX
@article{Zhang2024,
author = {Zhang, Yuming and Shan, Lianhai and Tang, Wentao and Ge, Yating and Li, ChengXian and Zhang, Jifa},
title = {Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications},
journal = {Journal of Medicinal Chemistry},
year = {2024},
volume = {67},
number = {7},
pages = {5185--5215},
doi = {10.1021/acs.jmedchem.4c00312}
}
EUVIMED